Texas Permanent School Fund Corp Sells 7,225 Shares of HCA Healthcare, Inc. $HCA

Texas Permanent School Fund Corp reduced its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 37.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,162 shares of the company’s stock after selling 7,225 shares during the period. Texas Permanent School Fund Corp’s holdings in HCA Healthcare were worth $4,659,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC purchased a new position in HCA Healthcare in the 4th quarter worth approximately $1,021,000. RWA Wealth Partners LLC boosted its holdings in shares of HCA Healthcare by 2.0% in the 1st quarter. RWA Wealth Partners LLC now owns 1,904 shares of the company’s stock worth $658,000 after purchasing an additional 37 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. lifted its position in HCA Healthcare by 5.0% in the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 30,667 shares of the company’s stock worth $10,598,000 after buying an additional 1,454 shares during the last quarter. HMS Capital Management LLC boosted its stake in shares of HCA Healthcare by 3.8% in the 1st quarter. HMS Capital Management LLC now owns 5,973 shares of the company’s stock valued at $1,969,000 after purchasing an additional 217 shares in the last quarter. Finally, Humankind Investments LLC grew its stake in shares of HCA Healthcare by 9.0% during the first quarter. Humankind Investments LLC now owns 4,704 shares of the company’s stock valued at $1,625,000 after buying an additional 387 shares during the last quarter. 62.73% of the stock is currently owned by institutional investors.

HCA Healthcare Stock Performance

Shares of NYSE:HCA opened at $471.55 on Thursday. HCA Healthcare, Inc. has a 52-week low of $289.98 and a 52-week high of $520.00. The firm has a market capitalization of $107.60 billion, a P/E ratio of 18.23, a P/E/G ratio of 1.39 and a beta of 1.36. The stock has a 50 day moving average price of $468.00 and a 200-day moving average price of $415.82.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Friday, October 24th. The company reported $6.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.64 by $1.32. The business had revenue of $19.16 billion during the quarter, compared to the consensus estimate of $18.55 billion. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.90 earnings per share. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. On average, equities analysts forecast that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 29th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, December 15th. HCA Healthcare’s dividend payout ratio (DPR) is presently 11.13%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on HCA. UBS Group raised their target price on shares of HCA Healthcare from $495.00 to $525.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Wells Fargo & Company upped their price objective on shares of HCA Healthcare from $412.00 to $431.00 and gave the company an “equal weight” rating in a research note on Thursday, November 13th. Cowen restated a “buy” rating on shares of HCA Healthcare in a report on Monday, October 27th. Wall Street Zen upgraded HCA Healthcare from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 25th. Finally, The Goldman Sachs Group upped their target price on HCA Healthcare from $470.00 to $520.00 and gave the company a “buy” rating in a report on Monday, October 27th. Fourteen analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $475.95.

Insider Buying and Selling at HCA Healthcare

In related news, EVP Michael R. Mcalevey sold 3,892 shares of the firm’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total transaction of $1,843,990.68. Following the completion of the transaction, the executive vice president owned 3,487 shares of the company’s stock, valued at $1,652,105.73. This trade represents a 52.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.30% of the stock is owned by insiders.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.